Clinical Trials Browser

Urinary Bladder Neoplasms × Cisplatin × Genitourinary × Clear all

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07106762 2026-03-10

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Active not recruiting

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06091124 2025-12-08

NEOBLAST

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1 Active not recruiting

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT03288545 2025-11-10

EV-103

Phase 1/2 Active not recruiting

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT01495676 2025-10-10

GETUGV04

Phase NA Terminated

69 enrolled 9 charts

Urinary Bladder Neoplasms

NCT07184021 2025-09-19

No Acronym

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Phase 2 Completed

17 enrolled 12 charts

Urinary Bladder Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2 Active not recruiting

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06571708 2025-09-02

NeoSTOP-IT

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03924856 2025-08-28

KEYNOTE-866

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06983210 2025-08-14

GRAPE

Phase 2 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02885974 2025-07-28

BLAST

Phase 1 Completed

Urinary Bladder Neoplasms

NCT04574960 2025-07-20

NAUTICAL

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05839119 2025-03-21

TASUC-Neo

Phase 1 Recruiting

Urinary Bladder Neoplasms

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1/2 Completed

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02807636 2025-02-24

IMvigor130

Phase 3 Completed

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02662062 2025-01-27

PCR-MIB

Phase 2 Completed

28 enrolled 15 charts

Urinary Bladder Neoplasms

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04241185 2024-11-25

MK-3475-992

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT00981656 2024-09-19

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Phase 2 Completed

37 enrolled 19 charts

Urinary Bladder Neoplasms

NCT02177695 2024-09-19

COXEN

Phase 2 Completed

237 enrolled 20 charts

Urinary Bladder Neoplasms

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03558087 2024-06-27

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Phase 2 Completed

76 enrolled 14 charts

Urinary Bladder Neoplasms

NCT06358599 2024-04-10

The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy

Urinary Bladder Neoplasms

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 9 charts

Urinary Bladder Neoplasms

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00003376 2023-06-22

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Phase 3 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00003701 2023-06-15

Combination Chemotherapy in Treating Patients With Bladder Cancer

Phase 3 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2 Completed

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms